For someone paralysed from the neck down, moving a computer cursor by thought is the difference between being cut off from a device and being able to run one. On 31 August 2026, Freiburg-based CorTec GmbH announced that FDA has granted a second Breakthrough Device Designation for the company’s Brain Interchange implant, covering computer cursor control for people with non-progressive quadriplegia, including spinal cord injury. CorTec’s first Breakthrough Designation, granted in April 2026, covered stroke motor rehabilitation. Both designations apply to the same underlying hardware.
FDA Breakthrough Device Designation provides prioritised, interactive review for devices addressing serious or irreversibly debilitating conditions. It does not constitute FDA marketing authorisation. The Brain Interchange remains investigational, limited by US law to research use.
Two designations on one implant
The Brain Interchange is a fully implantable, wireless, battery-free, bidirectional closed-loop BCI. Cortical surface electrodes sit on the brain without penetrating brain tissue, which is materially different from intracortical operators such as Neuralink and Paradromics that use penetrating electrode arrays. The same hardware serves both designated indications: recording cortical signals for decoding, and delivering targeted electrical stimulation for recovery.
CorTec CEO Dr Frank Desiere framed the second Designation, per the company release: “To our knowledge, only a handful of BCI companies worldwide, among them Neuralink and Paradromics, hold more than one FDA Breakthrough Device Designation, and no other system is designated for stroke motor rehabilitation.” The claim is attributed to CorTec, not asserted here as an independent count. Mara Assis is CorTec’s Head of Regulatory Affairs and Quality Management. Benedikt Kaiser is Head of Marketing.
Alongside its BCI clinical programme, CorTec operates a revenue-generating contract development and manufacturing organisation (CDMO) business supplying active implantable device components to third parties.
The clinical evidence
CorTec has published more than 500 days of continuous signal stability from the Brain Interchange in Nature Scientific Data (article s41597-025-06359-w). More than 50 CorTec cortical electrodes have been implanted in humans across more than a decade of the company’s clinical programmes.
The active clinical programme spans three sites disclosed in the 31 August release. At the University of Washington in Seattle, an FDA-approved Investigational Device Exemption (IDE) study is running on stroke motor rehabilitation, with three patients implanted to date. A UW study participant has already demonstrated computer control through thought using the same implant, which is the evidentiary bridge the FDA presumably weighed for the second Designation. At the Mayo Clinic, a registered epilepsy study (NCT05439655) has enrolled 13 patients. At UMC Utrecht in the Netherlands, an INTENSE communication study in paralysis is upcoming.
CorTec was accepted into the FDA Total Product Life Cycle Advisory Program (TAP) for its stroke programme on 23 April 2026. TAP is a relatively new FDA programme designed to compress medical device regulatory timelines through structured early engagement. Depression is listed among further indications under development.
Per CorTec’s own framing, the company is the first European operator to reach FDA-authorized clinical evaluation with a fully implantable bidirectional BCI system.
European BCI positioning
CorTec sits in the European BCI operator category alongside ABILITY Neurotech (Geneva, Munich intraoperative first-in-human 22 August 2026, UMC Utrecht and TU Graz chronic ALS trial in Q4 2026), Precision Neuroscience (US-headquartered with a European clinical footprint), INBRAIN Neuroelectronics (Barcelona, graphene neural interface, holds its own FDA Breakthrough Device Designation), and Neurable (US-headquartered non-invasive). Both CorTec’s Brain Interchange and ABILITY’s platform target UMC Utrecht as a clinical site: CorTec through the upcoming INTENSE communication study and ABILITY through the Q4 2026 chronic ALS trial with the INTRECOM consortium.
The non-penetrating cortical surface electrode architecture distinguishes CorTec from intracortical operators materially. Intracortical devices (Neuralink N1, Paradromics Connexus, Blackrock, StairMed WRS02) achieve higher-fidelity single-neuron signals at the cost of penetrating cortical tissue. Epicortical surface arrays (CorTec, ABILITY, Precision Neuroscience, Weiling Medical) trade signal fidelity for reduced surgical risk and simpler chronic implantation. Endovascular operators (Synchron, Nankai University’s Duan Feng team, Xuanwu Hospital’s Duan Wanru team) sit in a third category.
The European regulators are absent from the announcement
The strategic read on the 31 August release is not the second Breakthrough Designation itself. It is which regulator granted it. CorTec is a Freiburg-headquartered German company running two parallel FDA regulatory processes on identical hardware. The company’s clinical footprint spans the US (University of Washington, Mayo Clinic) and Europe (UMC Utrecht). The company is enrolled in a US FDA advisory programme. The European Medicines Agency and the CE Mark route through European notified bodies are absent from the announcement entirely.
Read across the European operator cohort, the pattern repeats: INBRAIN Neuroelectronics (Barcelona) holds an FDA Breakthrough Designation. ABILITY Neurotech (Geneva) has yet to publicly declare a US FDA regulatory footprint, but its clinical partners include US-connected consortium infrastructure. Precision Neuroscience runs its clinical work with FDA as the primary regulator. For capital-serious European implantable BCI operators, the primary commercial regulatory path is now FDA. Europe’s own regulators are not the near-term commercial gate.
Not disclosed
The specific date within August 2026 on which the FDA granted the second Breakthrough Designation is not disclosed; 31 August 2026 is the CorTec announcement date. The channel count and specific electrode array specification of the Brain Interchange are not restated in this release. The UMC Utrecht INTENSE study first-implant date is not disclosed. CorTec’s total lifetime funding, most recent round, and named investors are not disclosed. Any current EMA scientific advice or CE Mark technical documentation status is not disclosed in this release. Whether the same Brain Interchange hardware will also be used in the depression indication CorTec references is not confirmed.
What to watch
Watch whether CorTec files for a US FDA IDE amendment or IDE supplement for a communication indication study at UMC Utrecht or a US site. A Breakthrough Designation is a review-priority status; a follow-on IDE amendment for communication would move the second indication from designation to active clinical work.
Watch whether CorTec discloses first-implant data on the UMC Utrecht INTENSE communication study. First patient identity, date, safety profile, and cursor-control performance metrics would be the first operational read on the second-indication clinical trajectory.
Watch whether other European BCI operators (ABILITY, INBRAIN, Precision Neuroscience) publicly disclose FDA Breakthrough Designation activity or IDE filings in the coming months. A cluster of European operators moving through US FDA at the same time confirms the pattern: European implantable BCI is being commercialised through US regulatory channels first.
Watch whether the TAP participation shortens CorTec’s timeline to IDE completion and eventual PMA submission. Named TAP-participant milestones from CorTec would be the earliest indication that the programme is materially compressing the path to marketing authorisation.